Zobrazeno 1 - 10
of 274
pro vyhledávání: '"Ke-da Yu"'
Publikováno v:
Biomarker Research, Vol 12, Iss 1, Pp 1-19 (2024)
Abstract As one of the most common tumors in women, the pathogenesis and tumor heterogeneity of breast cancer have long been the focal point of research, with the emergence of tumor metastasis and drug resistance posing persistent clinical challenges
Externí odkaz:
https://doaj.org/article/2e9e3cb9942d46b6b7a5d88f5ea31ffe
Publikováno v:
Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-23 (2023)
Abstract Liquid–liquid phase separation (LLPS) is a novel principle for interpreting precise spatiotemporal coordination in living cells through biomolecular condensate (BMC) formation via dynamic aggregation. LLPS changes individual molecules into
Externí odkaz:
https://doaj.org/article/52be7b24b2744cbc95cbb98567436aca
Autor:
Wen-Jia Zuo, Li Chen, Yu Shen, Zhong-Hua Wang, Guang-Yu Liu, Ke-Da Yu, Gen-Hong Di, Jiong Wu, Jun-Jie Li, Zhi-Ming Shao
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Background: With our growing insight into the molecular heterogeneity and biological characteristics of breast cancer, individualized treatment is the future of cancer treatment. In this prospective Fudan University Shanghai Cancer Center Breast Canc
Externí odkaz:
https://doaj.org/article/0d7935c7ecb74a46860ea61e0ae9fa69
Autor:
Lie Chen, Cui-Cui Liu, Si-Yuan Zhu, Jing-Yu Ge, Yu-Fei Chen, Ding Ma, Zhi-Ming Shao, Ke-Da Yu
Publikováno v:
JCI Insight, Vol 8, Iss 22 (2023)
To provide complementary information and reveal the molecular characteristics and therapeutic insights of HER2-low breast cancer, we performed this multiomics study of hormone receptor–negative (HR–) and HER2-low breast cancer, also known as HER2
Externí odkaz:
https://doaj.org/article/439319fe74c34ccb980e5e7903108ad0
Publikováno v:
Cancer Communications, Vol 43, Iss 3, Pp 297-337 (2023)
Abstract Antibody‐drug conjugates (ADCs) are a rapidly developing therapeutic approach in cancer treatment that has shown remarkable activity in breast cancer. Currently, there are two ADCs approved for the treatment of human epidermal growth facto
Externí odkaz:
https://doaj.org/article/9dbcd28856d3452f9ad6c1a27c99a2b6
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-16 (2022)
Copy number alterations are pivotal genetic events in triple-negative breast cancer. Here the authors show the amplification of ENSA at the 1q21.3 region promotes the progression of TNBC via up-regulation of cholesterol biosynthesis.
Externí odkaz:
https://doaj.org/article/ed691364ebb04445bc384d80677c2aec
Autor:
Yi‐Ming Liu, Jing‐Yu Ge, Yu‐Fei Chen, Tong Liu, Lie Chen, Cui‐Cui Liu, Ding Ma, Yi‐Yu Chen, Yu‐Wen Cai, Ying‐Ying Xu, Zhi‐Ming Shao, Ke‐Da Yu
Publikováno v:
Advanced Science, Vol 10, Iss 6, Pp n/a-n/a (2023)
Abstract Breast cancer is now the most frequently diagnosed malignancy, and metastasis remains the leading cause of death in breast cancer. However, little is known about the dynamic changes during the evolvement of dissemination. In this study, 65 9
Externí odkaz:
https://doaj.org/article/3d649658179c4fd39a166f0e85ef2589
Publikováno v:
Cancer Communications, Vol 41, Iss 10, Pp 968-980 (2021)
Abstract Hormone receptor testing mainly serves the purpose of guiding treatment choices for breast cancer patients. Patients with estrogen receptor (ER)‐positive breast cancers show significant response to endocrine therapy. However, the methods t
Externí odkaz:
https://doaj.org/article/3b2ea1e1305e4654b01c5b440d7619b3
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
BackgroundThe optimal (neo)adjuvant regimen for human epidermal growth factor receptor-2 (HER2)-positive breast cancer regarding survival outcomes remains unclear.MethodsWe searched Web of Science, PubMed, and the Cochrane Central Register of Control
Externí odkaz:
https://doaj.org/article/0f6ac1d6c0eb41a6b0e830d0f590ba9e
Autor:
Guan-Tian Lang, Yi-Zhou Jiang, Jin-Xiu Shi, Fan Yang, Xiao-Guang Li, Yu-Chen Pei, Chen-Hui Zhang, Ding Ma, Yi Xiao, Peng-Chen Hu, Hai Wang, Yun-Song Yang, Lin-Wei Guo, Xun-Xi Lu, Meng-Zhu Xue, Peng Wang, A-Yong Cao, Hong Ling, Zhong-Hua Wang, Ke-Da Yu, Gen-Hong Di, Da-Qiang Li, Yun-Jin Wang, Ying Yu, Le-Ming Shi, Xin Hu, Wei Huang, Zhi-Ming Shao
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-13 (2020)
Chinese breast cancer patients have not been well represented in clinical sequencing studies. Here the authors analyse the mutational landscape of 1,134 Chinese breast cancer patients, finding actionable targets and a higher prevalence of p53 and Hip
Externí odkaz:
https://doaj.org/article/61dd0a122435489e99726b2dc7d128dc